Research Analysts Set Expectations for LMAT FY2024 Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Equities researchers at Roth Capital lifted their FY2024 earnings per share (EPS) estimates for shares of LeMaitre Vascular in a research report issued to clients and investors on Thursday, October 31st. Roth Capital analyst J. Wittes now forecasts that the medical instruments supplier will post earnings per share of $1.96 for the year, up from their prior forecast of $1.81. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.86 per share. Roth Capital also issued estimates for LeMaitre Vascular’s Q3 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.53 EPS, FY2025 earnings at $2.06 EPS, FY2026 earnings at $2.32 EPS and FY2027 earnings at $2.54 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the business posted $0.33 EPS.

Several other equities analysts also recently commented on the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Lake Street Capital initiated coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Oppenheimer reissued an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $94.88 on Monday. The company has a 50-day simple moving average of $89.59 and a 200-day simple moving average of $83.25. LeMaitre Vascular has a 52 week low of $45.96 and a 52 week high of $101.67. The firm has a market capitalization of $2.13 billion, a P/E ratio of 51.85, a P/E/G ratio of 2.32 and a beta of 0.89.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is 34.97%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is owned by insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently modified their holdings of LMAT. NBC Securities Inc. grew its position in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares during the last quarter. West Oak Capital LLC acquired a new stake in LeMaitre Vascular in the second quarter valued at approximately $58,000. USA Financial Formulas bought a new stake in shares of LeMaitre Vascular during the third quarter worth $60,000. Finally, nVerses Capital LLC increased its holdings in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.